Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway

Studies in humans have revealed that the pathogenesis of autism spectrum disorder (ASD) is linked to white matter abnormalities involving hypomyelination and oligodendroglia dysfunction; however, effective treatments remain limited. Similarly, the valproic acid (VPA) model mice, which are widely use...

Full description

Saved in:
Bibliographic Details
Main Authors: Chunyan Wen, Zhizhong Xu, Fengling Cao, Qianfa Yuan, Weichao Su, Zhiyuan Huang
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Brain Research Bulletin
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0361923025002436
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849687017243279360
author Chunyan Wen
Zhizhong Xu
Fengling Cao
Qianfa Yuan
Weichao Su
Zhiyuan Huang
author_facet Chunyan Wen
Zhizhong Xu
Fengling Cao
Qianfa Yuan
Weichao Su
Zhiyuan Huang
author_sort Chunyan Wen
collection DOAJ
description Studies in humans have revealed that the pathogenesis of autism spectrum disorder (ASD) is linked to white matter abnormalities involving hypomyelination and oligodendroglia dysfunction; however, effective treatments remain limited. Similarly, the valproic acid (VPA) model mice, which are widely used to study ASD, also exhibit white matter abnormalities with hypomyelination. Arecoline has been reported to enhance memory and cognition, facilitate myelination and improve neurological function. This study investigated the therapeutic potential of arecoline in a mouse model of prenatal VPA-induced ASD. We established an ASD mouse model through prenatal exposure to VPA and treated the mice with arecoline for 4 weeks. Behavioral analyses, including the elevated-plus maze, open field, self-grooming, marble-burying, three-chamber, Y-maze, and Morris water maze tests, were conducted to assess the effects of arecoline on behavior. Western blotting was used to detect changes in protein expression in the frontal cortex after arecoline treatment. The results revealed that offspring prenatally exposed to VPA presented characteristic behavioral abnormalities, including increased repetitive and stereotyped behaviors, deficits in social interaction, and impairments in learning and memory, accompanied by reduced expression of the myelin marker MBP and the mature oligodendrocyte marker GST-pi in the frontal cortex. Four-week arecoline treatment (1 and 2 mg/kg/day) significantly ameliorated these behavioral and cognitive abnormalities and restored myelination markers. Further mechanistic investigations demonstrated that arecoline enhanced the phosphorylation levels of AMPKα and CREB in the frontal cortex. This activation upregulated the expression of downstream BDNF, an essential neurotrophic factor for oligodendrocyte maturation and remyelination. These findings suggest that the AMPK/CREB/BDNF pathway may contribute to the therapeutic effects of arecoline, potentially through increased oligodendrocyte maturation and remyelination. This study provides preclinical evidence supporting arecoline as a potential myelination-targeting intervention, with implications for ASD and other neurological disorders involving myelination deficits.
format Article
id doaj-art-bdf5278920dc49139ecf61273d3f2fa1
institution DOAJ
issn 1873-2747
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series Brain Research Bulletin
spelling doaj-art-bdf5278920dc49139ecf61273d3f2fa12025-08-20T03:22:29ZengElsevierBrain Research Bulletin1873-27472025-09-0122911143110.1016/j.brainresbull.2025.111431Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathwayChunyan Wen0Zhizhong Xu1Fengling Cao2Qianfa Yuan3Weichao Su4Zhiyuan Huang5Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, Fujian 361012, ChinaFujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, Fujian 361012, ChinaFujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, Fujian 361012, ChinaFujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, Fujian 361012, ChinaFujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, Fujian 361012, ChinaCorrespondence to: Xiamen Xianyue Hospital, 387-399 Xianyue Road, Xiamen, Fujian 361012, China.; Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Xiamen, Fujian 361012, ChinaStudies in humans have revealed that the pathogenesis of autism spectrum disorder (ASD) is linked to white matter abnormalities involving hypomyelination and oligodendroglia dysfunction; however, effective treatments remain limited. Similarly, the valproic acid (VPA) model mice, which are widely used to study ASD, also exhibit white matter abnormalities with hypomyelination. Arecoline has been reported to enhance memory and cognition, facilitate myelination and improve neurological function. This study investigated the therapeutic potential of arecoline in a mouse model of prenatal VPA-induced ASD. We established an ASD mouse model through prenatal exposure to VPA and treated the mice with arecoline for 4 weeks. Behavioral analyses, including the elevated-plus maze, open field, self-grooming, marble-burying, three-chamber, Y-maze, and Morris water maze tests, were conducted to assess the effects of arecoline on behavior. Western blotting was used to detect changes in protein expression in the frontal cortex after arecoline treatment. The results revealed that offspring prenatally exposed to VPA presented characteristic behavioral abnormalities, including increased repetitive and stereotyped behaviors, deficits in social interaction, and impairments in learning and memory, accompanied by reduced expression of the myelin marker MBP and the mature oligodendrocyte marker GST-pi in the frontal cortex. Four-week arecoline treatment (1 and 2 mg/kg/day) significantly ameliorated these behavioral and cognitive abnormalities and restored myelination markers. Further mechanistic investigations demonstrated that arecoline enhanced the phosphorylation levels of AMPKα and CREB in the frontal cortex. This activation upregulated the expression of downstream BDNF, an essential neurotrophic factor for oligodendrocyte maturation and remyelination. These findings suggest that the AMPK/CREB/BDNF pathway may contribute to the therapeutic effects of arecoline, potentially through increased oligodendrocyte maturation and remyelination. This study provides preclinical evidence supporting arecoline as a potential myelination-targeting intervention, with implications for ASD and other neurological disorders involving myelination deficits.http://www.sciencedirect.com/science/article/pii/S0361923025002436Autism spectrum disorderCognitionMyelinationArecolineAMPK signaling pathway
spellingShingle Chunyan Wen
Zhizhong Xu
Fengling Cao
Qianfa Yuan
Weichao Su
Zhiyuan Huang
Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway
Brain Research Bulletin
Autism spectrum disorder
Cognition
Myelination
Arecoline
AMPK signaling pathway
title Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway
title_full Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway
title_fullStr Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway
title_full_unstemmed Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway
title_short Arecoline alleviates autism spectrum disorder-like behaviors and cognition disorders in a valproic acid mouse model by activating the AMPK/CREB/BDNF signaling pathway
title_sort arecoline alleviates autism spectrum disorder like behaviors and cognition disorders in a valproic acid mouse model by activating the ampk creb bdnf signaling pathway
topic Autism spectrum disorder
Cognition
Myelination
Arecoline
AMPK signaling pathway
url http://www.sciencedirect.com/science/article/pii/S0361923025002436
work_keys_str_mv AT chunyanwen arecolinealleviatesautismspectrumdisorderlikebehaviorsandcognitiondisordersinavalproicacidmousemodelbyactivatingtheampkcrebbdnfsignalingpathway
AT zhizhongxu arecolinealleviatesautismspectrumdisorderlikebehaviorsandcognitiondisordersinavalproicacidmousemodelbyactivatingtheampkcrebbdnfsignalingpathway
AT fenglingcao arecolinealleviatesautismspectrumdisorderlikebehaviorsandcognitiondisordersinavalproicacidmousemodelbyactivatingtheampkcrebbdnfsignalingpathway
AT qianfayuan arecolinealleviatesautismspectrumdisorderlikebehaviorsandcognitiondisordersinavalproicacidmousemodelbyactivatingtheampkcrebbdnfsignalingpathway
AT weichaosu arecolinealleviatesautismspectrumdisorderlikebehaviorsandcognitiondisordersinavalproicacidmousemodelbyactivatingtheampkcrebbdnfsignalingpathway
AT zhiyuanhuang arecolinealleviatesautismspectrumdisorderlikebehaviorsandcognitiondisordersinavalproicacidmousemodelbyactivatingtheampkcrebbdnfsignalingpathway